Little Science, Big Science--And Global Science

The handwriting for the future of federal science funding is on the wall, and Frank Press has read it as well as anybody. In his April 26th speech, the National Academy of Sciences president uttered publicly what many have acknowledged privately. The United States cannot afford to pursue at full tilt its Big Science agenda—the superconducting supercoilider, the human genome project, the space station—without cutting into support for the legions of individual investigators represe

Written byEugene Garfield
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The handwriting for the future of federal science funding is on the wall, and Frank Press has read it as well as anybody.

In his April 26th speech, the National Academy of Sciences president uttered publicly what many have acknowledged privately. The United States cannot afford to pursue at full tilt its Big Science agenda—the superconducting supercoilider, the human genome project, the space station—without cutting into support for the legions of individual investigators representing Little Science.

Press’s statement (The Scientist, May 30, 1988, page 1) has recognized what had already become a fractious debate between proponents of worthwhile Big Science projects and proponents of worthwhile Little Science projects. Indeed, it may have divided the camps even further. But why should scientists squabble over a single small pie when they can collectively bake a large one that feeds and sustains many?

Think for a moment how Derek J. de Solla Price ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies